Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Executive Moves

Beacon appoints Dr. Daniel Chung as CMO

Closely held Beacon Therapeutics announced the appointment of Dr. Daniel Chung as chief medical officer (CMO), effective immediately. Dr. Chung brings more than three decades of experience in ophthalmology, academic...

June 11, 2025

Executive Moves

Laura Conquergood joins Baylis as CEO

Closely held Baylis Medical Technologies announced the appointment of Laura Conquergood as chief executive officer (CEO). Kris Shah, formerly president and CEO, and Frank Baylis, formerly executive chairman, have both...

June 11, 2025

Developments

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that the first commercial benign prostatic hyperplasia (BPH) treatment utilizing the TULSA-PRO system’s new TULSA-AI Volume Reduction Module was successfully conducted...

June 10, 2025

Executive Moves

BioRestorative welcomes renowned industry leader, Sandy Lipkins, to BRTX team

BioRestorative Therapies (NASDAQ: BRTX) announced the addition of serial regenerative medicine entrepreneur, company builder, and leader, Sandy Lipkins, to focus on technology commercialization and business development...

June 10, 2025

Developments

Citius and Cardinal sign distribution agreement

Citius Oncology (NASDAQ: CTOR) announced it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH). According to Citius, the agreement is designed to help provide access to LYMPHIR, an...

June 9, 2025

Developments

Leef acquires New York License

Leef Brands (CSE: LEEF; OTCQB: LEEEF) announced it has officially closed on the acquisition of a Type 1 Cannabis Processor License in New York, enabling the company to engage in extraction, blending, infusion...

June 9, 2025

Executive Moves

FibroBiologics names Jason D. Davis as CFO

FibroBiologics (NASDAQ: FBLG) announced the appointment of Jason D. Davis, CPA, as chief financial officer (CFO), effective immediately. Bringing extensive experience in corporate finance, capital markets, and SEC...

June 9, 2025

Developments

Aytu signs agreement to commercialize Exxua for MDD

Aytu BioPharma (ASDAQ: AYTU) announced that it has signed an exclusive agreement with closely held Fabre-Kramer Pharmaceuticals to commercialize Exxua—extended-release antidepressant tablets—in the U.S. market for major...

June 9, 2025

Developments

Vaccines publishes key benefits of PharmaJet Tropis ID vaccine over IM SoC

Closely held PharmaJet announced that the results of an implementation research study—titled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An...

June 5, 2025

Developments

Perimeter launches OCT-Tissue Registry to power AI and imaging innovation

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced the launch of its optical coherence tomography (OCT)-Tissue Surveillance Registry—a database designed to collect thousands of images from surgical...

June 4, 2025

Subscribe